Filing Details

Accession Number:
0001127602-22-001144
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-07 16:15:17
Reporting Period:
2022-01-05
Accepted Time:
2022-01-07 16:15:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1631895 Shacey Petrovic C/O Insulet Corporation
100 Nagog Park
Acton MA 01720
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-05 15,000 $29.26 32,249 No 4 M Direct
Common Stock Disposition 2022-01-05 15,000 $264.97 17,249 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2022-01-05 15,000 $0.00 15,000 $29.26
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,070 2026-02-24 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 61,259 Indirect By NG Trust
Common Stock 6,401 Indirect By SP Trust
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
  2. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $255.02 to $276.67. Specifically: 775 shares were sold in the range of $255.02 to $255.99, with a weighted average share price of $255.59; 900 shares were sold in the range of $256.00 to $256.96, with a weighted average share price of $256.41; 1,000 shares were sold in the range of $257.09 to $257.94, with a weighted average share price of $257.61; 600 shares were sold in the range of $258.13 to $258.92, with a weighted average share price of $258.46; 702 shares were sold in the range of $259.05 to $259.71, with a weighted average share price of $259.45; 400 shares were sold in the range of $261.25 to $261.69, with a weighted average share price of $261.47; 600 shares were sold in the range of $262.08 to $262.70, with a weighted average share price of $262.26; 1,200 shares were sold in the range of $263.05 to $263.89, with a weighted average share price of $263.51; 1,479 shares were sold in the range of $264.08 to $264.88, with a weighted average share price of $264.60; 1,000 shares were sold in the range of $265.04 to $265.42, with a weighted average share price of $265.184; 400 shares were sold in the range of $266.37 to $266.83, with a weighted average share price of $266.48; 525 shares were sold in the range of $267.06 to $267.78, with a weighted average share price of $267.49; 1,624 shares were sold in the range of $268.00 to $268.98, with a weighted average share price of $268.30; 953 shares were sold in the range of $269.04 to $269.91, with a weighted average share price of $269.50; 500 shares were sold in the range of $270.05 to $270.86, with a weighted average share price of $270.54; 510 shares were sold in the range of $271.3 to $271.99, with a weighted average share price of $271.71; 300 shares were sold in the range of $272.07 to $272.44, with a weighted average share price of $272.32; 300 shares were sold in the range of $273.29 to $273.45, with a weighted average share price of $273.35; 600 shares were sold in the range of $274.12 to $274.83, with a weighted average share price of $274.64; 381 shares were sold in the range of $275.08 to $275.88, with a weighted average share price of $275.21; 251 shares were sold in the range of $276.28 to $276.67, with a weighted average share price of $276.52.The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  3. This option is subject to a four-year vesting period with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.